Pan-infection Pathogen Targeted Sequencing (PTseq™ plus) is based on pathogenic microorganism targeted next-generation sequencing (tNGS) technology. After targeted sample pre-processing, specific hybridization probes are used for targeted enrichment of target genes, and the sequencing is performed on high-throughput sequencing platform. It leverages high-quality, high-standard clinical-grade database comparison, combined with multiple patented technologies and intelligent biochemical analysis algorithms, to detect 729 pathogenic microorganisms, 66 drug resistance genes, and 64 virulence genes. PTseq™ plus can assist clinical identification of pathogenic microbial infection in samples, provide drug resistance and virulence gene test results, support the precise diagnosis and targeted treatment of infectious diseases.

• Applicable population

Individuals for whom clinical suspicion of pathogenic microbial infection exists and who require clarification of the infection cause, as well as patients in need of drug-resistant gene identification.

• Sample types

• Detection scope

PTseq plus can detect 729 pathogens and 130 representative drug resistance and virulence genes in a single test.

The solution includes all modules of instruments, reagents, analysis software, and tech-transfer service which can realize the whole process of sample processing, sequencing, and reporting locally.

*All sequencing platforms except DNBSEQ-E25 support mixed sample sequencing.

• PTseq™ plus Entire-process Detection

• Multiple sequencing platforms for diverse clinical needs

• Broad-spectrum coverage, identification of pathogenic microorganisms

1) A single test fully covers 729 kinds of clinically significant pathogen targets.

2) All-round drug resistance identification of bacteria, fungi, and viruses.

• High-Density Probe · Precision Capture

1) Hundreds of thousands of high-density probes enable multi-target coverage, with higher probe density provided for clinically significant and difficult-to-inspect pathogens to ensure the test sensitivity.

2) Adoption of the integrated probe design for all representative strains is adopted, retaining multiple overlapping probes in hypervariable regions, and eliminating redundant probes in conserved regions, enabling efficient capture.

3) Full-length coverage of drug resistance and virulence genes sequences, with higher probe density at drug resistance mutation sites, enhancing the sequencing depth and detection accuracy of drug resistance sites.

• Multidimensional Think Tank · Empowering Clinical Practices

1) Construction of a clinical pathogen sequence database, species annotation database, and background bacteria database adapted to various samples, enabling precise identification of pathogenic microorganisms.

2) Provision of comprehensive annotation information for the detected drug resistance and virulence genes, assisting in addressing the clinical application challenges of drug resistance gene detection, and enhancing the reference value of drug resistance results.

3) Self-built COVID-19 subtype database, updated in real-time to ensure subtyping accuracy.

• Efficient Detection · Outstanding Performance

1) Realization of ultra-sensitive detection through capture and enrichment, with a detection limit as low as 10 CFU(copies)/mL.

2) High-efficiency cell-free DNA fragment enrichment capability, improving the detection sensitivity in samples such as blood and cerebrospinal fluid. Compared with multiplex PCR targeted sequencing, the positive detection rate of sterile body fluid samples increases by 15% to 20%.

3) 1h rapid hybridization technology, significantly improving hybridization efficiency and speed, and reducing the detection time.

* TCID: A measuring unit for characterizing virus titer, the amount of virus required to cause half of the cells to become diseased or die in a 50-well plate or test tube.